🧫
CRISPR/Cas9-mediated humanization of mouse IgG1 Fc domain in hFCGRT transgenic mice
active
experiment
Created: 2026-04-10T14:43:28
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-515f882b-976d-41fa-a904-415b8fe7afce
🧫 Experiment Protocol
ValidationIGHG1B6.Cg-Fcgrttm1Dcr Tg(FCGRT)32Dcr transgenic miceproposed
This experiment involved using CRISPR/Cas9-mediated homology-directed repair to replace the mouse immunoglobulin heavy constant gamma 1 (IGHG1) Fc domain with the human IGHG1 Fc domain in hFCGRT transgenic mice (Tg32 strain). The goal was to create mice that produce human IgG1 Fc-mouse IgG Fab2 chimeric antibodies at physiologically relevant levels to better model human competitive conditions for IgG-based biologics. The engineered mice were designed to provide endogenous human IgG competition that more accurately reflects human physiology, addressing a recognized limitation of existing FcRn-humanized mouse models that lack endogenous human IgG.
PRIMARY OUTCOME
Production of human IgG1 Fc-mouse IgG Fab2 chimeric antibodies
EXPECTED OUTCOMES
Mice producing physiologically relevant levels of human IgG1 Fc-containing chimeric antibodies that can compete with administered humanized mAbs
SUCCESS CRITERIA
Production of chimeric IgG1 at physiologically relevant levels and demonstration of competitive effects on humanized mAb pharmacokinetics
PROTOCOL
CRISPR/Cas9-mediated homology-directed repair to replace mouse IGHG1 Fc domain with human IGHG1 Fc domain in hFCGRT transgenic mice
Source: PMID 33025844 ↗
🧫 Experiment Extras
PATHWAY
FcRn-mediated IgG recycling pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.